by Mark Curtis | Jun 25, 2014
. Welcome to your regenerative medicine deal review for the month of May. The space was quiet this past month; however, NeoStem did strike up a licensing deal with China-based Cellular Biomedicine Group to provide international reach to its newly acquired targeted...
by Lisa Willemse | Jun 3, 2014
> Bench to beside is a deceptively simple phrase. Only 15 characters and relatively jargon-free (assuming you know what bench and bedside are referring to), it’s rather easy to drop into documents or presentations without compromising space or time limits. And,...
by Mark Curtis | May 22, 2014
. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology...
by Stacey Johnson | May 16, 2014
. Last November, I wrote about CCRM’s new Regenerative Medicine Video Network and featured an original video with Dr. Stephen Minger, Chief Scientist, Cellular Sciences GE Healthcare Life Sciences in the UK. If you enjoyed his industry perspective and insights on...
by Mark Curtis | May 14, 2014
. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more....
by Mark Curtis | Apr 30, 2014
. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...
Comments